ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2023 and some content may be unavailable. To unlock all content for 2023, please visit the archives.

Abstract: SA-PO844

Humoral Immune Responses Primed by the Alteration of Gut Microbiota Were Associated with Galactose-Deficient IgA1 Production in IgA Nephropathy

Session Information

Category: Glomerular Diseases

  • 1401 Glomerular Diseases: From Inflammation to Fibrosis

Authors

  • Xie, Xinfang, Department of Nephrology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China
  • Gao, Li, Department of Nephrology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi’an, China
  • Li, Huixian, Department of Nephrology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi’an, China
  • Lu, Wanhong, Department of Nephrology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi’an, China
  • Lv, Jicheng, Renal Division, Peking University First Hospital; Peking University Institute of Nephrology, Beijing, China
  • Jin, Jing, Department of Medicine-Nephrology and Hypertension, Feinberg Cardiovascular and Renal Research Institute, Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States
Background

Galactose-deficient IgA1 (GdIgA1) is critical in the formation of immunodeposits in IgA nephropathy (IgAN), whereas the origin of GdIgA1 is unknown. We focused on the immune response to fecal microbiota in IgAN patients.

Methods

By running 16S rRNA gene sequencing, we compared IgAN samples to the control samples from household-matched or nonrelated individuals. Levels of plasma GdIgA1 and poly-IgA complexes were measured, and candidate microbes that can either incite IgA-directed antibody response or degrade IgA through specific IgA protease activities were identified.

Results

The IgAN group showed distinct composition of fecal microbiota as compared to healthy controls. Particularly, high abundance of Escherichia-Shigella was associated with the disease group based on analyses using Receiver-operating Characteristic (AUC 0.837, 95% CI 0.738-0.914), Principe Coordinates, and the LEfSe algorithm (LDA score: 4.56, p<0.001). Accordingly, the bacterial levels directly correlated with high titers of plasma GdIgA1(r=0.36, p<0.001), and patients had higher IgA1 against stx2(2.88±0.46 IU/ml vs. 1.34±0.35 IU/ml, p=0.03), the main antigen of Escherichia-Shigella. Conversely, the healthy controls showed relatively higher abundance of the commensal bacteria that produce IgA-degrading proteases. Particularly, the abundance of some intestinal bacteria expressing IgA proteases showed an inverse correlation with the levels of plasma GdIgA1 in IgAN.

Conclusion

Our data suggest that mucosal IgA production, including those of GdIgA1, is potentially linked to the immune reactivities against gut Escherichia-Shigella, and conversely, the IgA protease-producing microbiota in the gut are suppressed in IgAN patients.